Lead Product(s): Efinopegdutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM12525A
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: $870.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement August 04, 2020
Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.
Lead Product(s): HM15211
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM15211
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.